Drugs / 4SC-203
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01054937 | Jan → Nov 2010 | acute myeloid leukemia | 4SC AG | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SC-203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01054937 ↗ |
| Action | Inhibit | “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL5314406 ↗ |
| Modality | Small molecule | — CHEMBL5314406 ↗ |
| Route | Intravenous | “i.v. administration” NCT01054937 ↗ |
| Target | FLT3 | “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL5314406 ↗ |